Pulmonary Arterial Hypertension in a Patient with Multiple Sclerosis Treated with Interferon Beta: A Case Report

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216275%3A25520%2F16%3A39902053" target="_blank" >RIV/00216275:25520/16:39902053 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Pulmonary Arterial Hypertension in a Patient with Multiple Sclerosis Treated with Interferon Beta: A Case Report

Popis výsledku v původním jazyce

Pulmonary arterial hypertension (PAH) is characterized by elevation of mean pulmonary artery pressure to values conceivably approaching those seen in the systemic vascular bed. This occurrence is associated with a poor prognosis. PAH may result from a variety of causes, some of which are related to pharmacotherapy. Herein, we present a case of a 39-year-old female patient with relapsing-remitting multiple sclerosis (MS), who was receiving immunomodulatory therapy and subsequently developed severe PAH. We presume a causal relationship between the condition and the patient's interferon beta therapy, which had spanned 10 years. The interferon beta therapy was stopped because its continued administration could have led to more rapid progression of severe pulmonary hypertension. Due to the severity of pulmonary arterial hypertension, PAH-specific pharmacotherapy was indicated, using sildenafil. Since 1998, only several cases of pulmonary arterial hypertension in patients treated with interferon beta have been documented in the scientific literature. In some of these instances, including in two case studies involving patients with multiple sclerosis, it was concluded that there was a possible association with this therapy.

Název v anglickém jazyce

Pulmonary Arterial Hypertension in a Patient with Multiple Sclerosis Treated with Interferon Beta: A Case Report

Popis výsledku anglicky

Pulmonary arterial hypertension (PAH) is characterized by elevation of mean pulmonary artery pressure to values conceivably approaching those seen in the systemic vascular bed. This occurrence is associated with a poor prognosis. PAH may result from a variety of causes, some of which are related to pharmacotherapy. Herein, we present a case of a 39-year-old female patient with relapsing-remitting multiple sclerosis (MS), who was receiving immunomodulatory therapy and subsequently developed severe PAH. We presume a causal relationship between the condition and the patient's interferon beta therapy, which had spanned 10 years. The interferon beta therapy was stopped because its continued administration could have led to more rapid progression of severe pulmonary hypertension. Due to the severity of pulmonary arterial hypertension, PAH-specific pharmacotherapy was indicated, using sildenafil. Since 1998, only several cases of pulmonary arterial hypertension in patients treated with interferon beta have been documented in the scientific literature. In some of these instances, including in two case studies involving patients with multiple sclerosis, it was concluded that there was a possible association with this therapy.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Neurology and Neuroscience

ISSN

2171-6625

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

3

Strana od-do

72-74

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—